Isifundo 02B: Ukuphepha kanye nokusebenza ngempumelelo kwe-Pembrolizumab Ihlanganiswe Nama-ejenti Aphenyayo noma i-Pembrolizumab Yedwa Kubahlanganyeli Abanomugqa Wokuqala Othuthukisiwe We-melanoma

I-Substudy 02B iyingxenye yocwaningo olukhudlwana lapho abacwaningi befuna izindlela ezintsha zokwelapha i-melanoma ethuthukisiwe engakaze yelashwe ngaphambilini. Ucwaningo olukhulu luyisifundo esambulela. Abacwaningi bafuna ukwazi ukuthi ukwengeza ezinye izindlela zokwelapha ku-pembrolizumab kungayiphatha yini i-melanoma ethuthukisiwe. Imigomo yalolu cwaningo ukufunda:

* Mayelana nokuphepha nokuthi abantu bakubekezelela kahle kangakanani i-pembrolizumab enikezwa nezinye izindlela zokwelapha
* Bangaki abantu abane-melanoma esabelayo (ibancane noma iyahamba) ekwelashweni

Ingalo 1: I-Pembrolizumab + Vibostolimab yengezwe kuphrothokholi eyisisekelo ngomhla ka-13-Nov-2019, futhi ukubhaliswa kule ingalo sekuqediwe. Ingalo 2: I-Pembrolizumab yengezwe kuphrothokholi eyisisekelo ngomhla ka-13-Nov-2019, futhi ukubhaliswa kuma ngaphambi kwesikhathi ngomhla ka-15-Aug-2022. Ingalo 3: I-Coformulation Pembrolizumab/Quavonlimab yengezwe Ekuchitshiyelweni 01 ngomhla ka-20-Oct-2020, futhi ukubhaliswa kwema ngaphambi kwesikhathi ngomhla ka-15-Aug-2022. Ingalo 4: I-Coformulation Pembrolizumab/Quavonlimab + Lenvatinib yengezwe Ekuchitshiyelweni 01 ngomhla ka-20-Oct-2020, futhi ukubhaliswa kuyaqhubeka. Ingalo 5: I-Coformulation Favezelimab/Pembrolizumab yengezwe Ekuchitshiyelweni 03 ngomhla ka-01-DEC-2022 futhi imise ukubhalisa, Ingalo 6: I-Coformulation Favezelimab/Pembrolizumab + All-trans Retinoic Acid (ATRA) yengezwe Ekuchitshiyelweni 03 ngomhla ka-01-DEC-2022 futhi kumise ukubhaliswa, kanye ne-Arm 7: Ukuhlanganiswa kwe-Favezelimab/Pembrolizumab + Vibostolimab yengezwe Ekuchitshiyelweni 03 ngomhla ka-01-DEC-2022 futhi ukubhaliswa kwamiswa ngaphambi kwesikhathi ngomhla ka-22-SEP-2023.